Alec Stranahan
BofA Securities, Research Division

All right. Let's get going. Thanks for joining this session with Caribou Biosciences. My name is Alec Stranahan. I cover SMiD Biotech at Bank of America. And I'm pleased to welcome Rachel Haurwitz, President and CEO of Caribou. Thanks for being here, Rachel.

Rachel Haurwitz
Co-Founder, CEO, President & Director

Thanks so much for having us today, Alec.

Alec Stranahan
BofA Securities, Research Division

Yes. Great. Looking forward to the discussion. But maybe just for the benefit of the audience, those that have either not looked at Caribou for a little while or haven't seen the latest update, maybe you can give a high-level overview of what the company is doing and for the recent data that we've seen.

Rachel Haurwitz
Co-Founder, CEO, President & Director

Absolutely. Thank you. So Caribou is advancing two off-the-shelf CAR-T cell therapies. Vispa-cel targets CD19 for lymphoma and CB-011 targets BCMA for multiple myeloma. Each of these programs, we shared actually quite significant clinical updates towards the end of last year. And in both cases, we are seeing Phase I data that give us the confidence that each of these programs has best-in-class potential.

And I think what really unlocks unique outcomes for these patients is how we use our CRISPR technology platform. So we have our own proprietary next-generation CRISPR technology. We call it the chRDNA technology and its unique attribute is that it drives editing outcomes that are orders of magnitude more specific than first-generation CRISPR/Cas9.

And so we've leveraged that to edit to armor our cell